Scholar Rock Holding Corp — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) on September 11, 2026, for SMA in patients ≥2 years on SMN2-targeted therapy. Q3 2026 product revenue was $0.6M from initial shipments; early launch shows broad prescriber and patient demand across geographies and patient backgrounds. In November 2026, Scholar Rock signed a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $205M (non-dilutive capital). Cash position: $413.6M as of September 30, 2026. EMA resubmitted MAA validated in October 2026 (CHMP opinion expected H1 2027); Japan JNDA submitted and accepted under priority review. Net loss Q3 2026: $107.2M (vs. $102.2M Q3 2025); no material change in R&D ($54.1M) or SG&A ($52.5M) spend.
Why this rating
First marketed product launch materially changes business from preclinical to commercial; $205M PRV sale strengthens balance sheet. Revenue stage now, but still pre-peak; execution and market adoption risks remain. Significant relative to $2.6B market cap.
Tradability signal
NO TRADE
No trade: positive news with only -2.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: +0.10% over 4 hrs, n=202). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $51.13 | +10 min · unknown $49.69 ▼ 2.82% | +30 min · unknown $50.20 ▼ 1.82% | +1 hr · unknown $48.56 ▼ 5.01% | +4 hrs · unknown $48.79 ▼ 4.57% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.